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Summary
Objective: Recently we reported that glucosamine sulphate (GS) did not have an effect on the symptoms and progression of primary care
patients with hip osteoarthritis (OA). The aim of this present study was to investigate whether there are subgroups of patients with hip OA
for whom GS might be an effective therapy.
Method: We randomized 222 patients with hip OA that met one of the American College of Rheumatology criteria to either 1500 mg of oral GS
or placebo once daily for 2 years. Subgroup analyses were predeﬁned for radiographic severity (Kellgren & Lawrence (KL)¼ 1 vs 2) and for
type of OA (localised vs generalised). Additional exploratory subgroup analyses focused on groups based on pain level, pain medication use,
baseline joint space width (JSW), and concomitant knee OA at baseline.
Primary outcome measures were Western Ontario MacMaster Universities (WOMAC) pain and function scores over 24 months, and joint
space narrowing (JSN) after 24 months.
Results: In the predeﬁned subgroups based on radiographic severity and type of OA, the outcomes WOMAC pain, function and JSN were
similar for the GS and placebo group.
Conclusion: GS was not signiﬁcantly better than placebo in reducing symptoms and progression of hip OA in subgroups of patients.
ª 2008 Osteoarthritis Research Society International. Published by Elsevier Ltd. All rights reserved.
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The effect of glucosamine on the symptoms caused by oste-
oarthritis (OA) and the progression of the disease is still ques-
tionable. The summary effect of glucosamine on pain and
progression of the disease calculated from the available ran-
domized controlled trials (RCTs) is in favor of glucosamine1,2.
The individual results of the trials however differ greatly.
Part of the differences in outcome between different trials
may be explained by the compound used. A recent review2
concluded that glucosamine hydrochloride, as used by
GAIT3 and Messier et al.4, was not effective on OA
symptoms, whereas for glucosamine sulphate (GS) more
favorable results are reported. Furthermore, it was
suggested that differences in enrolled subjects, outcomes*Address correspondenceand reprint requests to: R.M.Rozendaal,
Erasmus MC, University Medical Center, Department of General
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427evaluated, and degree of co-intervention could be factors
explaining at least some of the differences5.
Our recently published independent long-term double-
blind RCT was the ﬁrst study to test the effect of GS in
patients with hip OA6. The results from this trial showed
that GS has no effect on the symptoms and radiographic
progression of hip OA in primary care patients.
When our trial was designed in 2003, not all trials on
glucosamine were uniformly positive7. Therefore, we
hypothesized that GS might show to be effective only for
a subgroup of OA patients. Severity of radiographic OA
has previously been suggested to have an inﬂuence on
the effect of GS8,9. Furthermore, it has been suggested
that generalized OA may have a different pathophysiology
than localized OA. We therefore hypothesized that type of
OA could have an inﬂuence on the effect of GS10.
In this study we perform predeﬁned and additional
exploratory subgroup analyses on the data of the original
trial to assess whether there are subgroups of patients
with hip OA for whom GS might be effective in modifying
symptomatic and radiographic progression.
428 R. M. Rozendaal et al.: Glucosamine for patients with hip OAMethodsDESIGN OVERVIEWData of our original study were used for subgroup analyses. This study
was a randomized blinded placebo-controlled trial with a duration of 2 years
in patients with hip OA6. All outcome assessors, patients and researchers in
this trial were blinded to therapy.
In the design of the study, a few of the subgroup analyses to assess the
effect of GS in subgroups of patients were pre-speciﬁed. The Medical Ethics
Committee of the Erasmus MC, University Medical Center, Rotterdam, the
Netherlands, approved the study design [MEC226.868/2003/72], and all
patients provided written informed consent.
A detailed study protocol was published in 200511. A brief summary of the
protocol is presented below.SETTING AND PARTICIPANTSGeneral practitioners in the Rotterdam area recruited patients. Patients
were eligible for inclusion when they met one of the criteria of the American
College of Rheumatology for hip OA12. This was screened at the research
centre. Patients that had undergone, or were on the waiting list for hip
replacement surgery were not included in the study. Patients were excluded
when they had a Kellgren & Lawrence (KL) score of 413, renal and/or hepatic
disease, diabetes mellitus or disabling co-morbidity. Patients already taking
GS, and those unable to ﬁll out Dutch questionnaires were also excluded.
Patients that violated study protocol or those who underwent total hip
arthroplasty were encouraged to stay in the study and ﬁll out questionnaires
to limit the loss to follow-up.
For the original study we randomly assigned 222 patients with hip OA to
either 1500 mg of GS once daily (in total 2000 mg of D-glucosamine sulphate
2 Potassium Chloride) or a placebo for the duration of 2 years. Both com-
pounds were manufactured by Nutricia Manufacturing USA, Inc. (Greenville,
South Carolina, United States of America) and provided by Numico
Research BV (Wageningen, the Netherlands).
The randomization was stratiﬁed to allow analyses in subgroups of pa-
tients. Patients were stratiﬁed on the basis of KL score (1 vs  2) and on
type of OA (localized vs generalized OA). Patients were considered to
have generalized OA when they had concomitant radiographic hand
and/or knee OA, deﬁned as a KL score of 2 or more. Patients with only
OA of the hip joint(s) were classiﬁed as having localized OA.
Besides the predeﬁned subgroups based on severity of radiographic OA
and type of OA, patients were also divided into groups based on baseline
level of pain assessed by a visual analogue scale (VAS) (30 vs >30)
and on joint space width (JSW) at baseline (2.5 mm vs <2.5 mm) for
exploratory analyses14. We also looked at the effect of treatment in a sub-
group of patients that did not use pain medication following the baseline
measurement. Finally we assessed whether there was an effect of GS in
a subgroup that had radiographic concomitant knee OA (KL 2) at baseline.Outcome measures
For the subgroup analyses we used the data from the
primary outcome measures that were used in the original
study. These measures were Western Ontario MacMaster
Universities (WOMAC) pain and function scores over
24 months15,16 and joint space narrowing (JSN) after 24
months. For the exploratory analyses we only report on
the outcomes for WOMAC pain and JSN.
At baseline and after 24 months a highly standardized
protocol was used to make weight bearing, anteroposterior
digital radiographs of the pelvis, to allow reliable measure-
ment of JSN. At baseline radiography of the hands and
knees was performed to assess KL score in these joints.
The minimal JSW was measured manually on our digital
radiographs, using a computer program (QBone Planner
5.4, manufactured by Medis, Leiden, the Netherlands).
The WOMAC (5-point Likert format), VAS for pain in past
week (0e100, 0 equals no pain), and pain medication (type
of pain medication and frequency of use: never, occasional,
and daily use) were assessed with a questionnaire that was
ﬁlled out at baseline and every 3 months thereafter; the last
at the end of the study after 24 months. The WOMAC sub-
scales are presented as normalized scores (0e100,
0 equals no complaints).In the case of bilateral hip complaints, patients were
asked to indicate their most affected hip. This hip was
used for the analyses of JSN. For patients with equivalent
pain in both hips, the hip with the highest KL score was
used, and in case the KL score was equal as well, the
hip with smallest internal rotation during a physical exam
was used.Statistical analysis
For the statistical analyses we used the data of all 3-
monthly questionnaires (i.e., baseline, and at 3, 6, 9, 12,
15, 18, 21, and 24 months). The outcomes are given as
a mean effect over 24 months incorporating all scores.
The analyses were performed with SPSS 11.0.1 (SPSS
inc., Chicago, IL) and SAS 8.2 (SAS Institute, Inc., Cary,
NC). The data were analyzed using linear mixed model
analyses, under the assumption that data are missing at
random. We chose an unstructured covariance structure
as this yielded the lowest Akaike’s information criterion.
Fixed effects were: time, time therapy, and the covariates
we adjusted for. Our model did not have random effects.
For patients who had total hip arthroplasty during the trial,
observed data before surgery were included in the analysis
and data after surgery were assumed missing. For patients
who were lost to follow-up, all observed data were included
in the analysis. The analyses for WOMAC and VAS pain
were adjusted for factors that may have had an inﬂuence on
symptoms, being body mass index, gender, and age 17,18.
Analyses were also adjusted for pain medication use and
unilateral/bilateral disease as these factors were not fully
balanced at baseline, and for KL score. The analyses for
JSN were adjusted for KL score19, age and gender20.
A total of 24 subgroup analyses were performed of which
20 were reported in the results section, on the basis of this
number at least one statistically signiﬁcant test (P< 0.05)
can be expected on the basis of chance alone.Results
In the original study 222 patients were included and
randomized to either GS or placebo. The two groups were
similar in baseline and demographic characteristics
(Table I), with the exception of an imbalance in daily pain
medication use and unilateral/bilateral disease. As stated
before these two factors will be adjusted for in the analyses.
The mean values of the outcome measures at baseline for
the different subgroups are given in Table II.SEVERITY OF RADIOGRAPHIC OAIn an adjusted analysis, the mean difference in WOMAC
pain scores over 24 months between GS and placebo in the
group with KL¼ 1 was 1.4 (95% CI [6.7, 3.8]) in favor of
GS (Table III). In the more severe group with KL 2 the
mean difference was 1.4 (95% CI [7.4, 4.7]). For
WOMAC function the mean difference between GS and pla-
cebo in the group with KL¼ 1 was 1.5 (95% CI [5.8, 2.9])
whereas this difference was 2.1 (95% CI [7.5, 3.3]) in the
group with KL 2. For the group with KL¼ 1 the mean
difference in JSN between GS and placebo was
0.09 mm (95% CI [0.22, 0.04]), in favor of placebo. In
the more severe group (KL 2) this difference was
0.09 mm (95% CI [0.07, 0.24]) in favor of GS.
Table I
Patient characteristics at baseline by randomized group
Characteristics All randomized
patients (N¼ 222)
Patients randomized
to placebo (N¼ 111)
Patients randomized
to GS* (N¼ 111)
Women, % 69.4 70.3 68.5
Age in years, mean (SDy) 63.4 (9.0) 63.7 (8.5) 63.1 (9.5)
Body mass index, mean (SD) 28 (4.7) 28 (4.9) 27.9 (4.5)
Duration of complaints< 1 yr, % 11.7 10.8 12.6
1e3 yrs, % 34.7 34.2 35.1
>3 yrs, % 53.6 55 52.3
Localised OAz, % 38.3 37.8 38.7
Generalised OA, % 61.7 62.2 61.3
Knee OA, % 30.6 30.6 30.6
Unilateral hip OA, % 51.8 38.7 64.9
Bilateral hip OA, % 48.2 61.3 35.1
Kellgren & Lawrence¼1, % 52.7 52.3 53.2
2, % 47.3 47.7 46.8
Minimum JSWx in mm, mean (SD) 2.23 (1.0) 2.33 (0.9) 2.13 (1.0)
JSW< 2.5 mm, % 53.6 48.6 58.6
WOMACk pain, mean (SD) 34.2 (23.1) 32.4 (23.2) 35.9 (23.0)
function, mean (SD) 35.1 (22.9) 34.1 (21.7) 36.0 (24.1)
stiffness, mean (SD) 42.6 (25.2) 41.1 (23.1) 44.2 (27.2)
Pain last week in mm, mean (SD) 32.4 (25.9) 30.5 (25.2) 34.3 (26.5)
VAS pain> 30, % 45.0 39.6 50.5
Pain medication use daily, % 23.9 18.9 28.8
sometimes, % 26.6 27.9 25.2
none, % 49.5 53.2 46.0
*GS: glucosamine sulfate.
ySD: standard deviation.
zOA: osteoarthritis.
xJSW: joint space width.
kWOMAC: Western Ontario Macmaster Universities.
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pain in the group with localized OA was 1.4 (95% CI [5.6,
8.3]) in favor of placebo whereas the mean difference in the
generalized subgroup was 3.5 (95% CI [8.2, 1.3]) in fa-
vor of GS (Table III). For WOMAC function the adjusted
analyses yielded a difference of 0.9 (95% CI [6.9, 5.1])
for localized OA and e2.9 (95% CI [7.0, 1.2]) for general-
ized OA. The mean difference in JSN was 0.02 (95% CI
[0.17, 0.13]) for the localized OA group and 0.05 (95%
CI [0.18, 0.08]) for the generalized OA group, both in favor
of the placebo group.Table I
Descriptive statistics at baseline
WOMAC pain
GS group
WOMAC pain
Placebo group
WOMAC
GS g
KL¼ 1 32.8 (23.3) 33.7 (24.7) 31.2 (
KL 2 39.5 (22.3) 30.9 (21.7) 41.4 (
Localized OA 34.8 (24.4) 27.3 (20.7) 35.3 (
Generalized OA 36.7 (22.2) 35.5 (24.3) 36.5 (
VAS 30 20.7 (16.3) 21.0 (14.9)
VAS> 30 50.9 (18.4) 49.7 (23.0)
No pain medication 24.0 (20.4) 22.3 (20.0)
Pain medication 43.7 (21.1) 41.5 (22.4)
No knee OA 35.2 (23.7) 29.8 (22.8)
Knee OA 37.5 (21.7) 38.2 (23.4)
JSW 2.5 mm
JSW< 2.5 mm
Values are presented as mean (SD).
*JSN: joint space narrowing.EXPLORATORY ANALYSESIn the group with a pain score at baseline of VAS 30,
the mean difference in WOMAC pain score was 2.4
(95% CI [7.1, 2.4]) (Table III). For the group with a pain
score at baseline of VAS> 30 the adjusted difference was
3.4 (95% CI [10.0, 3.2]) in favor of the GS group.
For patients not using pain medication during the study
the adjusted difference in WOMAC pain was 0.3 (95%
CI [6.4, 5.8]). For patients that used pain medication the
adjusted difference was 3.0 (95% CI [8.4, 2.5]).
For patients that had concomitant knee OA at baseline
the adjusted difference for WOMAC pain was 5.7 (95%I
for the different subgroups
function
roup
WOMAC function
Placebo group
JSN*
GS group
JSN Placebo
group
23.6) 34.3 (20.6) 0.09 (0.36) 0.01 (0.29)
23.7) 33.9 (22.9) 0.10 (0.26) 0.14 (0.35)
23.6) 29.0 (18.8) 0.07 (0.30) 0.07 (0.34)
24.6) 37.2 (22.8) 0.11 (0.35) 0.05 (0.31)
0.08 (0.34) 0.02 (0.31)
0.11 (0.32) 0.15 (0.31)
Table III
Effect of GS in subgroups
Change from baseline
after 24 months (SD)
Placebo group
Change from baseline
after 24 months (SD)
GS group
Unadjusted difference
after 24 months
(95% CI)
Adjusted difference
over 24 months
(95% CI)
Predeﬁned subgroup analyses
WOMAC pain* KL¼ 1 1.5 (26.0) 4.7 (19.3) 3.3 (11.9, 5.4) 1.4 (6.7, 3.8)z
KL 2 3.8 (26.8) 3.6 (21.8) 0.2 (11.3, 10.9) 1.35 (7.4, 4.7)z
WOMAC function* KL¼ 1 1.0 (18.1) 2.6 (19.0) 1.6 (8.6, 5.5) 1.5 (5.8, 2.9)z
KL 2 5.6 (21.3) 1.9 (19.3) 3.7 (12.8, 5.5) 2.1 (7.5, 3.3)z
JSNy KL¼ 1 0.01 (0.29) 0.09 (0.36) 0.10 (0.22, 0.03) 0.09 (0.22, 0.04)x
KL 2 0.14 (0.35) 0.10 (0.26) 0.03 (0.11, 0.17) 0.09 (0.07, 0.24)x
WOMAC pain* localized 1.8 (31.2) 1.1 (20.4) 2.9 (14.5, 8.8) 1.4 (5.6, 8.3)z
generalized 0.3 (22.8) 1.8 (21.1) 2.1 (10.4, 6.3) 3.5 (8.2, 1.3)z
WOMAC function* localized 1.2 (23.0) 2.2 (20.2) 3.4 (13.0, 6.2) 0.9 (6.9, 5.1)z
generalized 2.4 (17.3) 0.3 (18.3) 2.2 (9.0, 4.7) 2.9 (7.0, 1.2)z
JSNy localized 0.07 (0.34) 0.07 (0.30) 0.00 (0.14, 0.14) 0.02 (0.17, 0.13)x
generalized 0.05 (0.31) 0.12 (0.35) 0.07 (0.19, 0.06) 0.05 (0.18, 0.08)x
Exploratory analyses
WOMAC pain* VAS 30 6.1 (23.7) 1.1 (21.0) 5.0 (13.5, 3.5) 2.4 (7.1, 2.4)z
VAS> 30 8.0 (28.5) 4.5 (20.1) 3.5 (7.5, 14.5) 3.4 (10.0, 3.2)z
WOMAC pain No pain medication 4.0 (23.6) 1.1 (19.7) 2.9 (12.3, 6.4) 0.3 (6.4, 5.8)z
Pain medication 2.0 (28.5) 3.6 (21.3) 1.6 (11.5, 8.3) 3.0 (8.4, 2.5)z
WOMAC pain No knee OA 0.1 (26.2) 0.3 (21.5) 0.3 (7.9, 8.5) 0.1 (4.9, 4.7)z
Knee OA 2.9 (27.1) 5.8 (18.1) 8.7 (21.2, 3.8) 5.7 (12.6, 1.3)z
JSNy  2.5mm 0.02 (0.31) 0.08 (0.34) 0.10 (0.23, 0.03) 0.12 (0.26, 0.01)x
< 2.5mm 0.15 (0.31) 0.11 (0.32) 0.04 (0.09, 0.17) 0.04 (0.09, 0.18)x
*negative value: GS favours placebo.
ypositive value: GS favours placebo.
zadjusted for body mass index, gender, age, pain medication use, unilateral/bilateral disease, and Kellgren & Lawrence score.
xadjusted for gender, age, and Kellgren & Lawrence score.
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itant knee OA the difference was 0.1 (95% CI [4.9, 4.7]).
In the subgroup with a JSW of more than 2.5 mm at base-
line the adjusted difference in JSN was 0.12 (95% CI
[0.26, 0.01]) in favor of placebo. In the subgroup with
a JSW of less than 2.5 mm at baseline the adjusted differ-
ence in JSN is 0.04 (95% CI [0.09, 0.18]) and is more in
favor of GS.Discussion
Subgroup analyses in our trial did not show an effect of
GS on symptomatic or radiographic progression in sub-
groups of patients with hip OA. The predeﬁned subgroup
analyses based on radiographic severity of OA and type
of OA did not yield differences between GS and placebo
in outcomes for pain, function and JSN over 24 months.
None of the exploratory analyses based on pain medication
use, baseline pain level and JSW at baseline showed any
differences.
To get a sense of the magnitude of the effects we can
express the results for WOMAC pain and function as effect
sizes (ES). In order to reach a clinically relevant effect of
ES 0.5, we would need a difference of 11.5 points on
WOMAC pain and function outcomes. The ES of all trials
on glucosamine is 0.352, which can be interpreted as a small
effect. The average lower bound of the conﬁdence intervals
in our subgroup analyses was around 7, consistent with
an effect size of 0.3. This means that, despite the wider
conﬁdence intervals found in subgroup analyses, we can
practically rule out even a small effect of GS.
The possible positive effect of GS in patients with knee
OA1 raised the question whether the patients within our trialwith concomitant knee OA beneﬁted more from GS then the
patients without. We hypothesized that it would be possible
to ﬁnd such an effect in our trial, because complaints due to
knee OA are likely to have an inﬂuence on the WOMAC
questions for hip pain, in particular the ones regarding walk-
ing, ascending and descending stairs, and standing.
In the exploratory analysis on the patients with concomi-
tant radiographic knee OA at baseline, we found a mean
effect on WOMAC pain of 5.68 (95% CI [12.62, 1.26])
in favor of GS whereas the effect is almost 0 in patients
without concomitant knee OA. The ES for the lower bound
of the conﬁdence interval is 0.56 in favor of GS, this means
we cannot rule out a clinically relevant effect for knee OA.
This difference in effect between hip and knee OA may
be due to a difference in inﬂammatory component, which
is thought to be larger in knee OA. This assumption is
supported by the ﬁnding that some interventions targeting
inﬂammation seem to be more effective for knee than for
hip OA21,22. Also, in a study by Meulenbelt et al.23 knee
OA was positively associated with the inﬂammation compo-
nent, whereas hip OA was not.
That glucosamine acts on the inﬂammatory processes
was already shown by Uitterlinden et al.24, who found that
glucosamine protects against Interleukin-1b (IL-1b) medi-
ated extracellular matrix breakdown in in vitro studies.
IL-1b is one of the cytokines that plays an important role
in the inﬂammatory cascade in OA25.
However, the ﬁnding for knee OA may also be based on
chance alone, due to the multiple tests that we have
performed. Also, there is a chance of residual confounding,
especially since we did not have other information concern-
ing knee OA than a radiograph of the knees at baseline.
The patients in the original study had milder radiographic
OA than patients in previous positive trials26e28. While other
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the patients in this study had a KL score of 1. However,
when the effect of GS in a subgroup of patients with KL
score of 2 and 3 was tested, we still found no effect. The
outcomes in this subgroup were very similar to the
outcomes of the overall study population6 for WOMAC
pain and function.
In addition we performed a subgroup analysis based on
JSW, an objective measure of radiographic severity. With
a chosen cut-off value of 2.5 mm based on the literature29,
no effect of GS was seen in the two subgroups.
As far as we know we are the ﬁrst study to investigate the
relationship between type of OA and effect of a therapy.
It has been hypothesized that generalized OA may have
a different pathophysiology than localized OA10, which
could result in a different reaction to therapy. The results
from this current study do not necessarily support this
assumption, but they have implications for other studies
that study therapeutic effects on a single joint, in which
patients are included with OA in other joints as well. The
inﬂuence of co-existing disease in other joints should be
further investigated.
By performing predeﬁned and exploratory subgroup
analyses we increased the possibility of chance ﬁndings,
the results from our analyses should therefore be interpreted
with caution.We chose not to adjust formultiple comparisons.
The exploratory analyses were performed to answer ques-
tions that emerged during the main analyses, not to draw
conclusions on. Adjusting for multiple comparisons would
have increased the risk for a type II error. Finally, we found
no signiﬁcant differences without adjusting for multiple com-
parisons, adjusting for it would have led to even smaller ES.
For the sake of clarity we chose to report only the out-
comes for WOMAC pain in the exploratory subgroup analy-
ses. The outcomes for WOMAC function were very similar.
We made subgroups based on baseline level of VAS
pain with a cut-off value of 30 as this is often used in liter-
ature. In this analysis no differences were found between
GS and placebo. In the Glucosamine/chondroitin Arthritis
Intervention Trial (GAIT) study however, a subgroup of
patients with a high baseline level of pain (WOMAC
pain¼ 301e400 mm) was found to beneﬁt from the combi-
nation of glucosamine hydrochloride and chondroitin
sulphate3. We did not have enough patients with a level
of pain similar to the subgroup in the GAIT study to perform
a meaningful analysis on.
The patients in our study were receiving usual care
during the study. As a result, half of our patients used
pain medication daily or occasionally, as prescribed by their
general practitioner or as over-the-counter medication. To
rule out a dilution of effect due to pain medication use, we
assessed the effect of GS in a subgroup of patients that
reported no use of pain medication throughout the study
period. In this group with mild OA complaints (WOMAC
pain¼ 23.1 20.1 (MeanSD)) there was still no effect
of GS on pain and function.
In the design of this study subgroup analyses were
predeﬁned and the trial was oversized in order to have
sufﬁcient power to perform these analyses. However, the
standard deviation of the WOMAC pain and function data
in our study is much higher than was anticipated, probably
due to the inclusion of primary care patients. Future trials
with primary care patients should take this into consider-
ation when calculating the sample size. However, despite
the large standard deviations in our trial, we were able to
rule out minimal clinical important differences in almost all
analyses.Conclusion
GS was not better than placebo in reducing symptoms
and progression of hip OA in subgroups of patients based
on severity of radiographic OA, type of OA, severity of
pain at baseline, pain medication use and baseline JSW.Conﬂict of interest
The trial was designed and performed independently of
any pharmaceutical company. We received the study med-
ication to be tested from Numico Research BV free of
charge. The company was however in no way involved in
the design of the study or in any other aspect of the study.
All authors involved declare that they have no conﬂict of
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